Despite completing DRAP registration and obtaining Cabinet Committee approval, vital cancer and specialty medicines remain legally unavailable across the country due to delayed price notifications.
The Pakistan Pharmaceutical Manufacturers Association (PPMA) urges authorities to clear these pending price notifications immediately. Timely action is critical to prevent patients from relying on costly personal imports and to ensure uninterrupted access to life-saving treatments.
